Proteomics of Alzheimer's disease: Understanding mechanisms and seeking biomarkers

Expert Review of Proteomics

Volumn 4, Issue 2, 2007, Pages 227-238

  Lovestone, Simon ^a   Güntert, Andreas ^a   Hye, Abdul ^a   Lynham, Steven ^a   Thambisetty, Madhav ^a   Ward, Malcolm ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

2D gel electrophoresis; Alzheimer's disease; Amyloid; Biomarker; Isobaric tag; Mass spectrometry; Plaque; Tangle; Tau

Indexed keywords

ALBUMIN; ALPHA 2 MACROGLOBULIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN E; BETA 2 MICROGLOBULIN; BIOLOGICAL MARKER; CATHEPSIN D; CD5 ANTIGEN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4B; COMPLEMENT FACTOR H; CYSTATIN C; HEMOPEXIN; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; OROSOMUCOID; PREALBUMIN; RETINOL BINDING PROTEIN; TAU PROTEIN; TRYPSIN INHIBITOR;

ALZHEIMER DISEASE; BRAIN DAMAGE; DISEASE COURSE; GENE MUTATION; GENOME; HUMAN; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEOMICS; REVIEW; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; WESTERN BLOTTING;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; BIOLOGICAL MARKERS; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; HUMANS; MASS SPECTROMETRY; PROTEIN BINDING; PROTEOMICS;

EID: 34247101490     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/14789450.4.2.227     Document Type: Review

References (121)

1. Lowin A, Knapp M, McCrone P. Alzheimer's disease in the UK: comparative evidence on cost of illness and volume of health services research funding. Int. J. Geriatr. Psychiatry 16, 1143-1148 (2001).
2. Wilkins MR, Pasquali C, Appel RD et al. From proteins to proteomes: large scale protein identification by two-dimensional electrophoresis and amino acid analysis. Biotechnology (NY) 14, 61-65 (1996).
3. von Eggeling EF, Junker K, Fiedle W et al. Mass spectrometry meets chip technology: a new proteomic tool in cancer research? Electrophoresis 22, 2898-2902 (2001).
4. Gygi SP, Rist B, Gerber SA et al. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat. Biotechnol. 17, 994-999 (1999).
5. Steen H, Pandey A. Proteomics goes quantitative: measuring protein abundance. Trends Biotechnol. 20, 361-364 (2002).
6. Heck AJ, Krijgsveld J. Mass spectrometry-based quantitative proteomics. Expert. Rev. Proteomics 1, 317-326 (2004).
7. Kuhn K, Thompson A. Prinz T et al. Isolation of N-terminal protein sequence tags from cyanogen bromide cleaved proteins as a novel approach to investigate hydrophobic proteins. J. Proteome Res. 2, 598-609 (2003).
8. Thompson A, Schaefer J, Kuhn K et al. Tandem mass tags: a novel quantification strategy for comparative analysis of complex protein mixtures by MS/MS. Anal. Chem. 78, 4235 (2006).
9. Walsh DM, Klyubin I, Fadeeva JV et al. Amyloid-β oligomers: their production, toxicity and therapeutic inhibition. Biochem. Soc. Trans. 30, 552-557 (2002).
10. Watson D, Castano E, Kokjohn TA et al. Physicochemical characteristics of soluble oligomeric Aβ and their pathologic role in Alzheimer's disease. Neurol. Res. 27, 869-881 (2005).
11. Tseng BP, Kitazawa M, LaFerla FM. Amyloid β-peptide: the inside story. Curr. Alzheimer Res. 1, 231-239 (2004).
12. Mori H, Takio K, Ogawara M et al. Mass spectrometry of purified amyloid β protein in Alzheimer's disease. J. Biol. Chem. 267, 17082-17086 (1992).
13. Miller DL, Papayannopoulos IA, Styles J et al. Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer's disease. Arch. Biochem. Biophys. 301, 41-52 (1993).
14. Sergeant N, Bombois S, Ghestem A et al. Truncated β-amyloid peptide species in pre-clinical Alzheimer's disease as new targets for the vaccination approach. J. Neurochem. 85, 1581-1591 (2003).
15. Miravalle L, Calero M, Takao M et al. Amino-terminally truncated Aβ peptide species are the main component of cotton wool plaques. Biochemistry 44, 10810-10821 (2005).
16. Guntert A, Dobeli H, Bohrmann B. High sensitivity analysis of amyloid-β peptide composition in amyloid deposits from human and PS2APP mouse brain. Neuroscience 143, 461-475 (2006).
17. Liao L, Cheng D, Wang J et al. Proteomic characterization of postmortem amyloid plaques isolated by laser capture microdissection. J. Biol. Chem. 279(35), 37061-37068 (2004). •• Excellent example of a study combining advanced techniques (laser-capture microscopy and liquid chromatography tandem mass spectrometry). More evidence of axonal transport defects were demonstrated in Alzheimer's disease (AD) by showing dynein in the amyloid plaque.
18. Huang Y. Apolipoprotein E and Alzheimer disease. Neurology 66, S79-S85 (2006).
19. McGeer EG, Klegeris A, McGeer PL. Inflammation, the complement system and the diseases of aging. Neurobiol. Aging 26(Suppl. 1), 94-97 (2005).
20. Veerhuis R, Boshuizen RS, Familian A. Amyloid associated proteins in Alzheimer's and prion disease. Curr. Drug Targets CNS Neurol. Disord. 4, 235-248 (2005).
21. Schonberger SJ, Edgar PF, Kydd R et al. Proteomic analysis of the brain in Alzheimer's disease: molecular phenotype of a complex disease process. Proteomics 1, 1519-1528 (2001).
22. Tsuji T, Shimohama S. Analysis of the proteomic profiling of brain tissue in Alzheimer's disease. Dis. Markers 17, 247-257 (2001).
23. Butterfield DA, Boyd-Kimball D, Castegna A. Proteomics in Alzheimer's disease: insights into potential mechanisms of neurodegeneration. J. Neurochem. 86, 1313-1327 (2003).
24. Castegna A, Thongboonkerd V, Klein JB et al. Proteomic identification of nitrated proteins in Alzheimer's disease brain. J. Neurochem. 85, 1394-1401 (2003).
25. Vercauteren FG, Bergeron JJ, Vandesande F et al. Proteomic approaches in brain research and neuropharmacology. Eur. J. Pharmacol. 500, 385-398 (2004).
26. Gong CX, Liu F, Grundke-Iqbal I et al. Post-translational modifications of tau protein in Alzheimer's disease. J. Neural Transm. 112, 813-838 (2005).
27. Kopke E, Tung YC, Shaikh S et al. Microtubule-associated protein tau. Abnormal phosphorylation of a non-paired helical filament pool in Alzheimer disease. J. Biol. Chem. 268, 24374-24384 (1993).
28. Goedert M, Spillantini MG, Potier MC et al. Cloning and sequencing of the cDNA encoding an isoform of microtubuleassociated protein tau containing four tandem repeats: differential expression of tau protein mRNAs in human brain. EMBO J. 8, 393-399 (1989).
29. Stoothoff WH, Johnson GV. Tau phosphorylation: physiological and pathological consequences. Biochim. Biophys. Acta 1739, 280-297 (2005).
30. McLachlin DT, Chait BT. Analysis of phosphorylated proteins and peptides by mass spectrometry. Curr. Opin. Chem. Biol. 5, 591-602 (2001).
31. Carr SA, Huddleston MJ, Annan RS. Selective detection and sequencing of phosphopeptides at the fentomole level by mass spectrometry. Anal. Biochem. 239, 180-192 (1996).
32. Hanger DP, Betts JC, Loviny TL et al. New phosphorylation sites identified in hyperphosphorylated tau (paired helical filament-tau) from Alzheimer's disease brain using nanoelectrospray mass spectrometry. J. Neurochem. 71, 2465-2476 (1998).
33. 2+/ calmodulin-dependent protein kinase II as demonstrated tandem mass spectrometry. Neurosci. Lett. 353, 185-188 (2003).
34. Derkinderen P, Scales TM, Hanger DP et al. Tyrosine 394 is phosphorylated in Alzheimer's paired helical filament tau and in fetal tau with c-Abl as the candidate tyrosine kinase. J. Neurosci. 25, 6584-6593 (2005).
35. Reynolds CH, Betts JC, Blackstock WP et al. Phosphorylation sites on tau identified by nanoelectrospray mass spectrometry: differences in vitro between the mitogen-activated protein kinases ERK2, c-Jun N-terminal kinase and P38, and glycogen synthase kinase-3β. J. Neurochem. 74, 1587-1595 (2000).
36. Lund ET, McKenna R, Evans DB et al. Characterization of the in vitro phosphorylation of human tau by tau protein kinase II (cdk5/p20) using mass spectrometry. J. Neurochem. 76, 1221-1232 (2001).
37. Hensley K, Hall N, Subramaniam R et al. Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation. J. Neurochem. 65, 2146-2156 (1995).
38. Boyd-Kimball D, Sultana R, Fai PH et al. Proteomic identification of proteins specifically oxidized by intracerebral injection of amyloid β-peptide (1-42) into rat brain: implications for Alzheimer's disease. Neuroscience 132, 313-324 (2005).
39. Boyd-Kimball D, Poon HF, Lynn BC et al. Proteomic identification of proteins specifically oxidized in Caenorhabditis elegans expressing human Aβ(1-42): implications for Alzheimer's disease. Neurobiol. Aging 27(9), 1239-1249 (2005). • Using an experimental approach (in contrast to the observational studies that are the major focus of proteomics research in AD), this group shows convincingly that amyloid-β (Aβ) induces widespread protein oxidation in AD brain.
40. Opii WO, Joshi G, Head E et al. Proteomic identification of brain proteins in the canine model of human aging following a long-term treatment with antioxidants and a program of behavioral enrichment: relevance to Alzheimer's disease. Neurobiol. Aging (2006) (Epub ahead of print). • Another paper from the same group, which uses proteomics to demonstrate oxidative changes induced by Aβ. Together, these two papers provide an elegant demonstration of the power of proteomics and the utility of animal models beyond the transgenic mouse in AD research.
41. Poon HF, Castegna A, Farr SA et al. Quantitative proteomics analysis of specific protein expression and oxidative modification in aged senescence-accelerated-prone 8 mice brain. Neuroscience 126, 915-926 (2004).
42. Butterfield DA, Boyd-Kimball D. The critical role of methionine 35 in Alzheimer's amyloid β-peptide (1-42)-induced oxidative stress and neurotoxicity. Biochim. Biophys. Acta 1703, 149-156 (2005).
43. McGrath LT, McGleenon BM, Brennan S et al. Increased oxidative stress in Alzheimer's disease as assessed with 4-hydroxynonenal but not malondialdehyde. QJM 94, 485-490 (2001).
44. Calingasan NY, Uchida K, Gibson GE. Protein-bound acrolein: a novel marker of oxidative stress in Alzheimer's disease. J. Neurochem. 72, 751-756 (1999).
45. Butterfield DA, Perluigi M, Sultana R. Oxidative stress in Alzheimer's disease brain: new insights from redox proteomics. Eur. J. Pharmacol. 545, 39-50 (2006).
46. Levine RL, Williams JA, Stadtman ER et al. Carbonyl assays for determination of oxidatively modified proteins. Methods Enzymol. 233, 346-357 (1994).
47. Sultana R, Poon HF, Cai J et al. Identification of nitrated proteins in Alzheimer's disease brain using a redox proteomics approach. Neurobiol. Dis. 22, 76-87 (2006).
48. Sultana R, Boyd-Kimball D, Poon HF et al. Redox proteomics identification of oxidized proteins in Alzheimer's disease hippocampus and cerebellum: an approach to understand pathological and biochemical alterations in AD. Neurobiol. Aging 27, 1564-1576 (2006).
49. Castegna A, Aksenov M, Aksenova M et al. Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part I: creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. Free Radic. Biol. Med. 33, 562-571 (2002).
50. Lauderback CM, Hackett JM, Huang FF et al. The glial glutamate transporter, GLT-1, is oxidatively modified by 4-hydroxy-2-nonenal in the Alzheimer's disease brain: the role of Aβ1-42. J. Neurochem. 78, 413-416 (2001).
51. Butterfield DA, Poon HF, St Clair CD et al. Redox proteomics identification of oxidatively modified hippocampal proteins in mild cognitive impairment: insights into the development of Alzheimer's disease. Neurobiol. Dis. 22, 223-232 (2006).
52. Lutjohann D, Papassotiropoulos A, Bjorkhem I et al. Plasma 24Shydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patients. J. Lipid Res. 41, 195-198 (2000).
53. Hampel H, Mitchell A, Blennow K et al. Core biological marker candidates of Alzheimer's disease - perspectives for diagnosis, prediction of outcome and reflection of biological activity. J. Neural Transm. 111, 247-272 (2004).
54. van OM, Hofman A, Soares HD et al. Plasma Aβ(1-40) and Aβ(1-42) and the risk of dementia: a prospective case-cohort study. Lancet Neurol. 5, 655-660 (2006). • Very large study demonstrating that Aβ can be accurately measured in plasma and that it is associated with risk of dementia. This raises the possibility of plasma-based, proteomics-derived markers of AD.
55. Castano EM, Roher AE, Esh CL et al. Comparative proteomics of cerebrospinal fluid in neuropathologically-confirmed Alzheimer's disease and non-demented elderly subjects. Neurol. Res. 28, 155-163 (2006). •• Gel-based proteomics demonstrates widespread protein change in cerebrospinal fluid (CSF). Multiplexed biomarkers are the obvious conclusion from this work.
56. Finehout EJ, Franck Z, Relkin N et al. Proteomic analysis of cerebrospinal fluid changes related to postmortem interval. Clin. Chem. 52, 1906-1913 (2006).
57. Choe LH, Dutt MJ, Relkin N et al. Studies of potential cerebrospinal fluid molecular markers for Alzheimer's disease. Electrophoresis 23, 2247-2251 (2002).
58. Puchades M, Hansson SF, Nilsson CL et al. Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease. Brain Res. Mol. Brain Res. 118, 140-146 (2003).
59. Finehout EJ, Franck Z, Lee K.H. Complement protein isoforms in CSF as possible biomarkers for neurodegenerative disease. Dis. Markers 21, 93-101 (2005). • Another candidate-based protein study. This paper offers further evidence of a widespread change in complement activation in AD.
60. Davidsson P, Westman-Brinkmalm A, Nilsson CL et al. Proteome analysis of cerebrospinal fluid proteins in Alzheimer patients. Neuroreport 13, 611-615 (2002).
61. Finehout EJ, Franck Z, Choe LH, Relkin N, Lee KH. Cerebrospinal fluid proteomic biomarkers for Alzheimer's disease. Ann. Neurol. 61, 120-129 (2007). •• See [69].
62. Davidsson P, Folkesson S, Christiansson M et al. Identification of proteins in human cerebrospinal fluid using liquid-phase isoelectric focusing as a prefractionation step followed by two-dimensional gel electrophoresis and matrix-assisted laser desorption/ionisation mass spectrometry. Rapid Commun. Mass Spectrom. 16, 2083-2088 (2002).
63. Davidsson P, Puchades M, Blennow K. Identification of synaptic vesicle, pre- and postsynaptic proteins in human cerebrospinal fluid using liquid-phase isoelectric focusing. Electrophoresis 20, 431-437 (1999).
64. Hesse C, Bogdanovic N, Davidsson P et al. A quantitative and immunohistochemical study on apolipoprotein E in grain tissue in Alzheimer's disease. Dementia 10, 452-459 (1999).
65. Sheta EA, Appel SH, Goldknopf IL. 2D gel blood serum biomarkers reveal differential clinical proteomics of the neurodegenerative diseases. Expert. Rev. Proteomics 3, 45-62 (2006). •• Notes that blood-based biomarkers are feasible in AD. We agree with the conclusions that gel-based approaches have much to offer.
66. Zolotarjova N, Martosella J, Nicol G et al. Differences among techniques for high-abundant protein depletion. Proteomics 5, 3304-3313 (2005).
67. Lopez MF, Mikulskis A, Kuzdzal S et al. High-resolution serum proteomic profiling of Alzheimer disease samples reveals disease-specific, carrier-protein-bound mass signatures. Clin. Chem. 51, 1946-1954 (2005).
68. Zhang R, Barker L, Pinchev D et al. Mining biomarkers in human sera using proteomic tools. Proteomics 4, 244-256 (2004).
69. Hye A, Lynham S, Thambisetty M et al. Proteome-based plasma biomarkers for Alzheimer's disease. Brain 129, 3042-3050 (2006). •• Our study and Finehout et al [61] both use proteomics combined with multivariate analyses to identify putative markers of AD. These are important papers showing the potential of proteomic approaches in both plasma and CSF. Both fluids may be productive sources of biomarkers: CSF, as a sample fluid closer to disease, is likely to show a greater signal (as suggested by a comparison of the data from these two papers). Plasma, as a sample fluid that is easier to access, would be easier to use in the clinical setting. Both approaches are likely to be pursued vigorously to find the best combination of specificity and utility.
70. Liu HC, Hu CJ, Chang JG et al. Proteomic identification of lower apolipoprotein A-I in Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 21, 155-161 (2006).
71. Carrette O, Demalte I, Scherl A et al. A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease. Proteomics 3, 1486-1494 (2003). • Although a small study, this early demonstration that surface-enhanced laser desorption/ionization analysis of CSF can be used as a potential diagnostic marker for AD was important.
72. Lewczuk P, Esselmann H, Groemer TW et al. Amyloid β peptides in cerebrospinal fluid as profiled with surface enhanced laser desorption/ionization time-of-flight mass spectrometry: evidence of novel biomarkers in Alzheimer's disease. Biol. Psychiatry 55, 524-530 (2004).
73. Maddalena AS, Papassotiropoulos A, Gonzalez-Agosti C et al. Cerebrospinal fluid profile of amyloid β peptides in patients with Alzheimer's disease determined by protein biochip technology. Neurodegener. Dis. 1, 231-235 (2004). •• Rather than attempting to profile the proteome, these authors have profiled the range of amyloid peptides in CSF. This is important both for the understanding of the metabolism of amyloid precursor protein and as a potential biomarker that is potentially more specific than Aβ42.
74. Zhang J, Goodlett DR, Quinn JF et al. Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease. J. Alzheimers Dis. 7, 125-133 (2005).
75. Abdi F, Quinn JF, Jankovic J et al. Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J. Alzheimers Dis. 9, 293-348 (2006). •• One of the first studies to use multiplexed mass spectrometry-based approaches for biomarker discovery. This is an impressive paper and perhaps a sign of future developments in proteomics of AD.
76. Veerhuis R, Van Breemen MJ, Hoozemans JM et al. Amyloid β plaque-associated proteins C1q and SAP enhance the Aβ1-42 peptide-induced cytokine secretion by adult human microglia in vitro. Acta Neuropathol. (Berl.) 105(2), 135-144 (2003).
77. Zhan SS, Veerhuis R, Kamphorst W, Eikelenboom P. Distribution of β amyloid associated proteins in plaques in Alzheimer's disease and in the non-demented elderly. Neurodegeneration 4(3), 291-297 (1995).
78. Weggen S, Diehlmann A, Buslei R, Beyreuther K, Bayer TA. Prominent expression of presenilin-1 in senile plaques and reactive astrocytes in Alzheimer's disease brain. Neuroreport 9(14), 3279-3283 (1998).
79. Masliah E, Iwai A, Mallory M, Ueda K, Saitoh T. Altered presynaptic protein NACP is associated with plaque formation and neurodegeneration in Alzheimer's disease. Am. J. Pathol. 148(1), 201-210 (1996).
80. Ferrer I, Blanco R, Carmona M et al. Prion protein expression in senile plaques in Alzheimer's disease. Acta Neuropathol. (Berl.) 101(1), 49-56 (2001).
81. Namba Y, Tomonaga M, Kawasaki H, Otomo E, Ikeda K. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res. 541(1), 163-166 (1991).
82. Porchet R, Probst A, Bouras C, Draberova E, Draber P, Riederer BM. Analysis of glial acidic fibrillary protein in the human entorhinal cortex during aging and in Alzheimer's disease. Proteomics 3(8), 1476-1485 (2003).
83. Griffin WS, Sheng JG, Roberts GW, Mrak RE. Interleukin-1 expression in different plaque types in Alzheimer's disease, significance in plaque evolution. J. Neuropathol. Exp. Neurol. 54(2), 276-281 (1995).
84. Hull M, Berger M, Volk B, Bauer J. Occurrence of interleukin-6 in cortical plaques of Alzheimer's disease patients may precede transformation of diffuse into neuritic plaques. Ann. NY Acad. Sci. 777, 205-212 (1996).
85. Perry G, Friedman R, Shaw G, Chau V. Ubiquitin is detected in neurofibrillary tangles and senile plaque neurites of Alzheimer disease brains. Proc. Natl Acad. Sci. USA 84(9), 3033-3036 (1987).
86. Bernstein HG, Ansorge S, Riederer P, Reiser M, Frolich L, Bogerts B. Insulin-degrading enzyme in the Alzheimer's disease brain prominent localization in neurons and senile plaques. Neurosci. Lett. 263(2-3), 161-164 (1999).
87. 2-macroglobulin expression in neuritic-type plaques in patients with Alzheimer's disease. Neurobiol. Aging 14(3), 233-237 (1993).
88. Gollin PA, Kalaria RN, Eikelenboom P, Rozemuller A, Perry G. α1-antitrypsin and α1-antichymotrypsin are in the lesions of Alzheimer's disease. Neuroreport 3(2), 201-203 (1992).
89. Bernstein HG, Bruszis S, Schmidt D, Wiederanders B, Dorn A. Immunodetection of cathepsin D in neuritic plaques found in brains of patients with dementia of Alzheimer type. J. Hirnforsch 30(5), 613-618 (1989).
90. Guo H, Albrecht S, Bourdeau M, Petzke T, Bergeron C, LeBlanc AC. Active caspase-6 and caspase-6-cleaved tau in neuropil threads, neuritic plaques, and neurofibrillary tangles of Alzheimer's disease. Am. J. Pathol. 165(2), 523-531 (2004).
91. Rufenacht P, Guntert A, Bohrmann B, Ducret A, Dobeli H. Quantification of the Aβ peptide in Alzheimer's plaques by laser dissection microscopy combined with mass spectrometry. J. Mass Spectrom. 40(2), 193-201 (2005).
92. Brion JP, Couck AM, Bruce M, Anderton B, Flament-Durand J. Synaptophysin and chromogranin A immunoreactivities in senile plaques of Alzheimer's disease. Brain Res. 539(1), 143-150 (1991).
93. Chaudhury AR, Gerecke KM, Wyss JM, Morgan DG, Gordon MN, Carroll SL. Neuregulin-1 and erbB4 immunoreactivity is associated with neuritic plaques in Alzheimer disease brain and in a transgenic model of Alzheimer disease. J. Neuropathol. Exp. Neurol. 62(1), 42-54 (2003).
94. Mitchelmore C, Buchmann-Moller S, Rask L, West MJ, Troncoso JC, Jensen NA. NDRG2, a novel Alzheimer's disease associated protein. Neurobiol. Dis. 16(1), 48-58 (2004).
95. Siegel DA, Davies P, Dobrenis K, Huang M. Tomoregulin-2 is found extensively in plaques in Alzheimer's disease brain. J. Neurochem. 98(1), 34-44 (2006).
96. Nakamura Y, Takeda M, Yoshimi K et al. Involvement of clathrin light chains in the pathology of Alzheimer's disease. Acta Neuropathol. (Berl.) 87(1), 23-31 (1994).
97. Burbach GJ, Hellweg R, Haas CA et al. Induction of brain-derived neurotrophic factor in plaque-associated glial cells of aged APP23 transgenic mice. J. Neurosci. 24(10), 2421-2430 (2004).
98. Nakamura S, Arima K, Haga S et al. Fibroblast growth factor (FGF)-9 immunoreactivity in senile plaques. Brain Res. 814(1-2), 222-225 (1998).
99. van der Wal EA, Gomez-Pinilla F, Cotman CW. Transforming growth factor-β1 is in plaques in Alzheimer and Down pathologies. Neuroreport 4(1), 69-72 (1993).
100. Yasuhara O, Muramatsu H, Kim SU, Muramatsu T, Maruta H, McGeer PL. Midkine, a novel neurotrophic factor, is present in senile plaques of Alzheimer disease. Biochem. Biophys. Res. Commun. 192(1), 246-251 (1993).
101. Birecree E, Whetsell WO Jr, Stoscheck C, King LE Jr, Nanney LB. Immunoreactive epidermal growth factor receptors in neuritic plaques from patients with Alzheimer's disease. J. Neuropathol. Exp. Neurol. 47(5), 549-560 (1988).
102. Morrison JH, Rogers J, Scherr S, Benoit R, Bloom FE. Somatostatin immunoreactivity in neuritic plaques of Alzheimer's patients. Nature 314(6006), 90-92 (1985).
103. Lovell MA, Robertson JD, Teesdale WJ, Campbell JL, Markesbery WR. Copper, iron and zinc in Alzheimer's disease senile plaques. J. Neurol. Sci. 158(1), 47-52 (1998).
104. Falangola MF, Lee SP, Nixon RA, Duff K, Helpern JA. Histological co-localization of iron in Aβ plaques of PS/APP transgenic mice. Neurochem. Res. 30(2), 201-205 (2005).
105. Suh SW, Jensen KB, Jensen MS et al. Histochemically-reactive zinc in amyloid plaques, angiopathy, and degenerating neurons of Alzheimer's diseased brains. Brain Res. 852(2), 274-278 (2000).
106. Grundke-Iqbal I, Fleming J, Tung YC, Lassmann H, Iqbal K, Joshi JG. Ferritin is a component of the neuritic (senile) plaque in Alzheimer dementia. Acta Neuropathol. (Berl.) 81(2), 105-110 (1990).
107. Snow AD, Mar H, Nochlin D et al. Early accumulation of heparan sulfate in neurons and in the β-amyloid protein-containing lesions of Alzheimer's disease and Down's syndrome. Am. J. Pathol. 137(5), 1253-1270 (1990).
108. Snow AD, Mar H, Nochlin D, Kresse H, Wight TN. Peripheral distribution of dermatan sulfate proteoglycans (decorin) in amyloid-containing plaques and their presence in neurofibrillary tangles of Alzheimer's disease. J. Histochem. Cytochem. 40(1), 105-113 (1992).
109. van Horssen HJ, Wilhelmus MM, Heljasvaara R et al. Collagen XVIII, a novel heparan sulfate proteoglycan associated with vascular amyloid depositions and senile plaques in Alzheimer's disease brains. Brain Pathol. 12(4), 456-462 (2002).
110. Burns MP, Noble WJ, Olm V et al. Co-localization of cholesterol, apolipoprotein E and fibrillar Aβ in amyloid plaques. Brain Res. Mol. Brain Res. 110(1), 119-125 (2003).
111. Lee SC, Zhao ML, Hirano A, Dickson DW. Inducible nitric oxide synthase immunoreactivity in the Alzheimer disease hippocampus, association with Hirano bodies, neurofibrillary tangles, and senile plaques. J. Neuropathol. Exp. Neurol. 58(11), 1163-1169 (1999).
112. Ferrer I, Marti E, Lopez E, Tortosa A. NF-κB immunoreactivity is observed in association with β A4 diffuse plaques in patients with Alzheimer's disease. Neuropathol. Appl. Neurobiol. 24(4), 271-277 (1998).
113. Bayer TA, Paliga K, Weggen S, Wiestler OD, Beyreuther K, Multhaup G. Amyloid precursor-like protein 1 accumulates in neuritic plaques in Alzheimer's disease. Acta Neuropathol. (Berl.) 94(6), 519-524 (1997).
114. Namba Y, Ouchi Y, Takeda A, Ueki A, Ikeda K. Bleomycin hydrolase immunoreactivity in senile plaque in the brains of patients with Alzheimer's disease. Brain Res. 830(1), 200-202 (1999).
115. Wirths O, Multhaup G, Czech C et al. Reelin in plaques of β-amyloid precursor protein and presenilin-1 double-transgenic mice. Neurosci. Lett. 316(3), 145-148 (2001).
116. Reiser G, Bernstein HG. Neurons and plaques of Alzheimer's disease patients highly express the neuronal membrane docking protein p42IP4/centaurin α. Neuroreport 13(18), 2417-2419 (2002).
117. Masliah E, Mallory M, Alford M, Hansen LA, Saitoh T. Immunoreactivity of the nuclear antigen p105 is associated with plaques and tangles in Alzheimer's disease. Lab. Invest. 69(5), 562-569 (1993).
118. Namba Y, Tsuchiya H, Ikeda K. Apolipoprotein B immunoreactivity in senile plaque and vascular amyloids and neurofibrillary tangles in the brains of patients with Alzheimer's disease. Neurosci. Lett. 134(2), 264-266 (1992).
119. Desai PP, Ikonomovic MD, Abrahamson EE et al. Apolipoprotein D is a component of compact but not diffuse amyloid-β plaques in Alzheimer's disease temporal cortex. Neurobiol. Dis. 20(2), 574-582 (2005).
120. Martin-Rehrmann MD, Hoe HS, Capuani EM, Rebeck GW. Association of apolipoprotein J-positive β-amyloid plaques with dystrophic neurites in Alzheimer's disease brain. Neurotox Res. 7(3), 231-242 (2005).
121. Issaq HJ, Veenstra TD, Conrads TP, Felschow D. The SELDI-TOF MS approach to proteomics: protein profiling and biomarker identification. Biochem. Biophys. Res. Commun. 293(3), 587-592 (2002).